FDA Approves Avastin for Recurrent Ovarian Cancer (U.S.)

Medpage


Published: Nov 14, 201WASHINGTON -- The FDA has approved the angiogenesis inhibitor bevacizumab (Avastin) for use in combination with paclitaxel to treat platinum-resistant recurrent #ovarian cancer.
The approval was based on results of an international, phase III, randomized trial to compare paclitaxel alone with paclitaxel plus bevacizumab. Known as AURELIA, the trial involved 361 women whose ovarian cancer had recurred less than 6 months after their most recent platinum-based chemotherapy regimen.
The trial had a final endpoint of progression-free survival (PFS), and the results demonstrated a 62% reduction in the hazard for progression or death in patients who received bevacizumab.........